ALK, anaplastic lymphoma kinase; NSCLC, metastatic non-small cell lung cancer; TKI, tyrosine kinase inhibitor.

1. Peters S, et al. N Engl J Med 2017;377:819–838. 2. Mok T, et al. Ann Oncol 2020;31:1056–1064. 3. Peters S, et al. Ann Oncol 2025. DOI: 10.1016/j.annonc.2025.09.018. 4. Wu YL, et al. N Engl J Med 2024;390:1265–1276. 5. Dziadziuszko R, et al. J Thorac Oncol 2021;16:2040–2050. 6. Gadgeel SM, et al. Ann Oncol 2023;34:S782–S783. 7. Wolf J, et al. ESMO Open 2022;7:100333. 8. Nakagawa K, et al. Lung Cancer 2020;139:195–199. 9. Novello S, et al. Annals Oncol 2018;29:1409–1416. 10. Arrieta O, et al. Nat Commun 2025;16:4553. 11. Barlesi F, et al. Ann Oncol 2016;27(Supplement 6):vi416–vi545. 12. Yang JCH, et al. Thorac Oncol 2017;12:1552–1560. 13. Ou SH, et al. J Clin Oncol 2016;34:661–668. 14. Shaw AT, et al. Lancet Oncol 2016;17:234–242. 15. Dziadziuszko R, et al. Updated results from the Phase III ALINA study of adjuvant alectinib vs chemotherapy in patients with early stage ALK+ non-small cell lung cancer (NSCLC). ESMO. 17–21 October 2025. Berlin, Germany. 16. ALECENSA Summary of Product Characteristics. 17. Zhou Z, et al. Transl Lung Cancer Res 2022;11:2495–2506. 18. DiBonaventura MD, et al. OncoTargets Ther 2018;11:75–82. 19. Hizal M, et al. Future Oncol 2022;18:2573–2582. 20. Masuda N, et al. Cancer Sci 2019;110:1401–1407. 21. Wang M, et al. Target Oncol 2023;18:571–583. 22. Yang X, et al. Transl Lung Cancer Res 2025;14:1158–1167. 23. Zhang Q, et al. JTO Clin Res Rep 2023;4:100483. 24. Roche. Data on File.

© 2025 F. Hoffmann-La Roche Ltd. M-XX-00021690; Date of preparation: December 2025 Legal Statement - Privacy Policy - Cookie Preferences